Zydus Lifesciences moves up on launching Lenalidomide Capsules in US
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 371.00, up by 11.30 points or 3.14% from its previous closing of Rs. 359.70 on the BSE.
The scrip opened at Rs. 359.35 and has touched a high and low of Rs. 370.40 and Rs. 359.35 respectively. So far 23797 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 572.90 on 04-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 377.90 and Rs. 355.55 respectively. The current market cap of the company is Rs. 37492.04 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 14.88% and 10.24% respectively.
Zydus Lifesciences has launched Lenalidomide Capsules in the US. The company had earlier received final approvals for 5 mg, 10 mg, 15 mg and 25 mg strengths and tentative approvals for 2.5 mg and 20 mg strength.
Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). The drug is being manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India. Lenalidomide had annual sales of $2.86 billion in the United States, according to IQVIA MAT July 2022.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.
